Continuing Education: Reviewing Interleukin 17– and Interleukin 23–targeting Therapies and Best Practices in Psoriatic Disease Management Featuring Clinical Practice Video Vignettes

Pharmacy TimesMarch 2020
Volume 88
Issue 3

These diseases are chronic, inflammatory, and autoimmune in nature, affecting the skin and often the joints.


Michael Crowe, PharmD, MBA, CSP, FMPA, Registered Manager of General Operations at Community, A Walgreens Pharmacy, in Flint, Michigan; Adjunct Assistant Professor of Clinical Pharmacy at Ferris State University College of Pharmacy in Big Rapids, Michigan

At the conclusion of this activity, the participant will be able to:

  • Investigate the pathophysiology of psoriatic disease with a focus on the interleukin 17 and interleukin 23 pathways
  • Explore the mechanism of action, safety, efficacy, and role in therapy for current and emerging interleukin 17 and interleukin 23 antagonist biologics for the treatment of psoriasis and/or psoriatic arthritis
  • Determine best practices for specialty pharmacists in the management of psoriatic disease

Target Audience: Specialty pharmacists, specialty pharmacy directors/managers, health-system pharmacists, formulary decision makers, and other pharmacists involved in the care of patients with psoriatic disease

Activity Type: Application

Release Date: March 16, 2020

Expiration Date: June 16, 2021

Estimated Time to Complete Activity: 2 hours

Fee: This lesson is offered for free at

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.